E
Nirvana Life Sciences Inc. NIRV
CNSX
Recommendation
Prev Close
Volume
--
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)

10/31/2024 07/31/2024 04/30/2024 01/31/2024 10/31/2023
Net Income 63.95% 84.89% 50.70% 102.30% 39.95%
Total Depreciation and Amortization -- -- -73.37% -47.06% --
Total Amortization of Deferred Charges -- -- -- -- --
Total Other Non-Cash Items -39.94% -100.06% -73.92% -27,150.00% 5,533.33%
Change in Net Operating Assets -91.12% 66.12% 264.17% -35.33% -62.38%
Cash from Operations 59.54% 98.98% 91.52% 65.76% 40.28%
Capital Expenditure -- -- -- -- --
Sale of Property, Plant, and Equipment -- -- -- -- --
Cash Acquisitions -- -- -- -- --
Divestitures -- -- -- -- --
Other Investing Activities -- -- -- -- --
Cash from Investing -- -- -- -- --
Total Debt Issued 176.47% -33.75% 113.90% -91.45% -77.22%
Total Debt Repaid -- -- -- -- -100.00%
Issuance of Common Stock -- -- -- -- --
Repurchase of Common Stock -- -- -- -- --
Issuance of Preferred Stock -- -- -- -- --
Repurchase of Preferred Stock -- -- -- -- --
Total Dividends Paid -- -- -- -- --
Other Financing Activities -- -- -- -- --
Cash from Financing -2.82% -96.22% -94.01% -91.33% -39.06%
Foreign Exchange rate Adjustments -- -- -- -- --
Miscellaneous Cash Flow Adjustments -- -- -- -- --
Net Change in Cash 89.32% -96.31% -114.75% -336.36% 41.94%
Weiss Ratings